Obesity-Related Hypertension

REFERENCES

1. ↵
   1. Laragh J. H.

   (1989) Presentation of the Harvey Award to Arthur C. Guyton. Am J Hypertens 2(7):573–574, pmid:2667574.

   OpenUrlCrossRefPubMed
2. ↵
   1. Frohlich E. D.

   (2002) Clinical management of the obese hypertensive patient. Cardiol Rev 10(3):127–138, pmid:12047791.

   OpenUrlCrossRefPubMed
3. ↵
   1. Hall J. E.

   (2000) Pathophysiology of obesity hypertension. Curr Hypertens Rep 2(2):139–147, pmid:10981140.

   OpenUrlCrossRefPubMed
4. ↵
   1. Hall J. E.,
   2. Crook E. D.,
   3. Jones D. W.,
   4. Wofford M. R.,
   5. Dubbert P. M.

   (2002) Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324(3):127–137, pmid:12240710.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Wofford M. R.,
   2. Hall J. E.

   (2004) Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 10(29):3621–3637, pmid:15579059.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Wofford M. R.,
   2. Anderson D. C. Jr.,
   3. Brown C. A.,
   4. Jones D. W.,
   5. Miller M. E.,
   6. Hall J. E.

   (2001) Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 14(7, pt 1):694–698, pmid:11465655.

   OpenUrlCrossRefPubMed
7. 1. Victor R. G.,
   2. Shafiq M. M.

   (2008) Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep 10(3):241–247, pmid:18765097.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Sarzani R.,
   2. Salvi F.,
   3. Dessì-Fulgheri P.,
   4. Rappelli A.

   (2008) Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 26(5):831–843, pmid:18398321.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Bloomgarden Z. T.

   (2002) Obesity, hypertension, and insulin resistance. Diabetes Care 25(11):2088–2097, pmid:12401761.

   OpenUrlFREE Full Text
10. ↵
    1. Re R. N.

    (2001) The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol 16(6):317–327, pmid:11704700.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Greenfield J. R.,
    2. Miller J. W.,
    3. Keogh J. M.,
    4. et al.

    (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360(1):44–52, pmid:19092146.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Dzau V. J.,
    2. Re R.

    (1994) Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 89(1):493–498, pmid:8281685.

    OpenUrlFREE Full Text
13. ↵
    1. Engeli S.

    (2008) Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 20(suppl 1):110–115, pmid:18426509.

    OpenUrlCrossRefPubMedWeb of Science
14. 1. Sarzani R.

    (2008) Endocannabinoids, blood pressure and the human heart. J Neuroendocrinol 20(suppl 1):58–62, pmid:18426501.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Grassi G.,
    2. Quarti-Trevano F.,
    3. Seravalle G.,
    4. Arenare F.,
    5. Brambilla G.,
    6. Mancia G.

    (2008) Blood pressure lowering effects of rimonabant in obesity-related hypertension. J Neuroendocrinol 20(suppl 1):63–68, pmid:18426502.

    OpenUrlPubMed
16. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Ventura H. O.,
    4. Cardenas G. A.,
    5. Mehra M. R.,
    6. Messerli F. H.

    (2007) Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 100(9):1460–1464, pmid:17950808.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Toprak A.,
    2. Wang H.,
    3. Chen W.,
    4. Paul T.,
    5. Srinivasan S.,
    6. Berenson G.

    (2008) Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am J Cardiol 101(11):1621–1625, pmid:18489940.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Philip-Couderc P.,
    2. Smih F.,
    3. Hall J. E.,
    4. et al.

    (2004) Kinetic analysis of cardiac transcriptome regulation during chronic high-fat diet in dogs. Physiol Genomics 19(1):32–40, pmid:15226482.

    OpenUrlCrossRefPubMed
19. ↵
    1. Zhou Y.,
    2. Poczatek M. H.,
    3. Berecek K. H.,
    4. Murphy-Ullrich J. E.

    (2006) Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 339(2):633–641, pmid:16310163.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Wenzel U. O.,
    2. Krebs C.

    (2007) Management of arterial hypertension in obese patients. Curr Hypertens Rep 9(6):491–497, pmid:18367013.

    OpenUrlCrossRefPubMedWeb of Science
21. 1. Mark A. L.

    (2007) Weight reduction for treatment of obesity-associated hypertension: nuances and challenges. Curr Hypertens Rep 9(5):368–372, pmid:18177582.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Mark A. L.

    (2006) Dietary therapy for obesity is a failure and pharmacotherapy is the future: a point of view. Clin Exp Pharmacol Physiol 33(9):857–862, pmid:16922821.

    OpenUrlCrossRefPubMed
23. ↵
    1. Re R. N.

    (1987) The renin-angiotensin systems. Med Clin North Am 71(5):877–895, pmid:3306208.

    OpenUrlPubMed
24. ↵
    1. Francischetti E. A.,
    2. Celoria B. M.,
    3. Francischetti A.,
    4. Genelhu V. A.

    (2008) Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther 6(3):289–303, pmid:18327991.

    OpenUrlCrossRefPubMed